Back to top
more

PDS Biotechnology (PDSB)

(Real Time Quote from BATS)

$2.86 USD

2.86
174,864

-0.06 (-1.89%)

Updated Jun 10, 2024 12:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PDSB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

PDS Biotechnology Corporation [PDSB]

Reports for Purchase

Showing records 41 - 60 ( 63 total )

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 41

10/04/2021

Daily Note

Pages: 4

VERSATILE-002 Completes Enrollment of CKI Naive Cohort; First Look at Results on the Horizon

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 42

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PDSB

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 43

08/12/2021

Company Report

Pages: 11

2Q21 Results; Visibility Keeps Increasing on Programs; Target Reduced to $15 on Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 44

06/08/2021

Company Report

Pages: 11

Versamune Based PDS0101 Impresses at ASCO in Phase 2 NCI Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 45

06/03/2021

Company Report

Pages: 7

Data Support Casting a Wider Net in VERSATILE-002

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 46

06/02/2021

Company Report

Pages: 7

Sea Change in Thesis and Visibility Happening Before Our Eyes; Target Upped to $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 47

05/20/2021

Company Report

Pages: 6

NCI PDS0101 Study Impresses Early in ASCO Abstract; No Wonder it Received an Oral Presentation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 48

05/13/2021

Company Report

Pages: 7

1Q21 Results; Advancing Oncology and Infectious Disease Pipelines Signal Exciting Year Ahead

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 49

03/19/2021

Company Report

Pages: 7

2020 Results; All Eyes on PDS0101 for HPVCancers and COVID-Vaccine

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 50

03/11/2021

Daily Note

Pages: 4

Capital Injection Paves Way for Versamune Based COVID-19 Vaccine in Latin America

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 51

02/22/2021

Daily Note

Pages: 5

COVID-19 Program Strengthened; Meaningful Updates on PDS0101 in HPV-Associated Cancers in 2Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 52

02/03/2021

Company Report

Pages: 7

PDS0101 Hits Initial Efficacy Thresholds in HPVAssociated Cancers; Key Data Expected in 2Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 53

12/22/2020

Company Report

Pages: 6

A Recipe for Success; Versamune Continues to be a Valuable Addition to Vaccine Formulations

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 54

11/12/2020

Company Report

Pages: 6

3Q20 Results; Continued Progress in All Programs With a Renewed Focus on COVID-19

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 55

11/10/2020

Company Report

Pages: 6

Trials Open for Business Again; Thesis Getting Back on Track; Upgrade to Buy, $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 56

06/15/2020

Daily Note

Pages: 4

PDS0101 Begins Dosing in HPV-Associated Cancers

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 57

06/05/2020

Daily Note

Pages: 4

PDS0101 Finds a Collaborator to Begin Phase 2 Studies in Cervical Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 58

05/13/2020

Company Report

Pages: 7

1Q20 Results; Trials Ready to Get Started as COVID-19 Vaccine Percolates

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 59

04/30/2020

Company Report

Pages: 7

NCI CRADA Expanded; Further Discussion on Infectious Disease Approach

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 60

04/17/2020

Company Report

Pages: 6

Entering the COVID-19 Vaccine Mix as Oncology Pauses Continue

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party